Closed · RFA-CA-10-502 · CFDA 93.393;93.394;93.395;93.396;93.399 · Discretionary
AIDS Malignancy Clinical Trials Consortium (Limited Competition U01)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- March 3, 2010
- Close date
- -
- Expected awards
The verdict
AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.393;93.394;93.395;93.396;93.399
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
AIDS Malignancy Clinical Trials Consortium is closed (last close March 3, 2010). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed March 3, 2010
Est. Total Funding
$4,680,000
Instrument
Cooperative Agreement
Description
Purpose. The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international importance in HIV-associated-malignancies; and 5) distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The award will provide subcontracts for a coordinating center, core sites, affiliate sites, network laboratories and a statistical center. Sites will receive patient care costs on a capitation basis and for laboratory correlative studies, clinical pharmacology and international studies. The group will have at least four scientific disease-oriented working groups (WG) - KS, lymphoma, HPV-associated cancers, and non-AIDS-Defining Cancers (NADCs) Working Groups . Mechanism of Support. This FOA will use the NIH U01 cooperative agreement award mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that $ 4.68 million for year one will be available for this initiative, and one application is expected to be awarded.
Campus applicant desk · Education
Grants.gov prints only higher-education applicant doors for AIDS Malignancy Clinical Trials Consortium (Public / state-controlled institutions of higher education). This reads as a campus competition desk, not a civic or commercial open call. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 173 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 06
- Public / state-controlled institutions of higher education
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
AIDS Malignancy Clinical Trials Consortium is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.394;93.395;93.396;93.399 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |